Boxer Capital Management LLC Acquires New Holdings in MoonLake Immunotherapeutics $MLTX

Boxer Capital Management LLC bought a new position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 250,000 shares of the company’s stock, valued at approximately $1,792,000. MoonLake Immunotherapeutics accounts for approximately 0.6% of Boxer Capital Management LLC’s holdings, making the stock its 25th largest holding. Boxer Capital Management LLC owned about 0.39% of MoonLake Immunotherapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Elevation Point Wealth Partners LLC bought a new position in shares of MoonLake Immunotherapeutics during the second quarter valued at $74,000. Bank of America Corp DE grew its stake in shares of MoonLake Immunotherapeutics by 64.7% in the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after purchasing an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after purchasing an additional 3,166 shares during the last quarter. Covestor Ltd bought a new position in MoonLake Immunotherapeutics during the 3rd quarter worth $46,000. Finally, BNP Paribas Financial Markets raised its position in MoonLake Immunotherapeutics by 18.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock worth $52,000 after purchasing an additional 1,158 shares during the last quarter. 93.85% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on MLTX shares. UBS Group set a $24.00 target price on MoonLake Immunotherapeutics in a report on Friday, January 9th. Royal Bank Of Canada increased their price target on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the company a “sector perform” rating in a research note on Monday, March 2nd. Zacks Research raised MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Needham & Company LLC upped their target price on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Finally, HC Wainwright increased their target price on shares of MoonLake Immunotherapeutics from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics presently has a consensus rating of “Hold” and a consensus target price of $27.85.

MoonLake Immunotherapeutics Stock Performance

Shares of MLTX opened at $17.13 on Friday. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75. The company has a market cap of $1.23 billion, a PE ratio of -4.87 and a beta of 1.20. The stock has a 50-day moving average of $16.52 and a 200-day moving average of $20.50. The company has a debt-to-equity ratio of 0.24, a current ratio of 9.27 and a quick ratio of 9.27.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.92). During the same period last year, the company earned ($0.72) EPS. On average, equities research analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.